Kyverna Therapeutics Inc. [KYTX] stock is trading at $7.88, down -2.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KYTX shares have gain 8.39% over the last week, with a monthly amount drifted -39.71%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kyverna Therapeutics Inc. [NASDAQ: KYTX] stock has seen the most recent analyst activity on July 03, 2024, when H.C. Wainwright initiated its Neutral rating and assigned the stock a price target of $8. Previously, Wells Fargo started tracking the stock with Overweight rating on March 04, 2024, and set its price target to $44. On March 04, 2024, Morgan Stanley initiated with a Overweight rating and assigned a price target of $40 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $48 on March 04, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $39 as its price target on March 04, 2024.
Kyverna Therapeutics Inc. [KYTX] stock has fluctuated between $6.75 and $35.06 over the past year. Kyverna Therapeutics Inc. [NASDAQ: KYTX] shares were valued at $7.88 at the most recent close of the market.
Analyzing the KYTX fundamentals
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.20 points at the first support level, and at 6.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.17, and for the 2nd resistance point, it is at 8.67.
Ratios To Look Out For
For context, Kyverna Therapeutics Inc.’s Current Ratio is 17.17. Also, the Quick Ratio is 17.17.
Transactions by insiders
Recent insider trading involved GILEAD SCIENCES, INC., 10% Owner, that happened on Feb 12 ’24 when 0.91 million shares were purchased. Former 10% Owner, Northpond Ventures III GP, LLC completed a deal on Feb 12 ’24 to buy 0.45 million shares. Meanwhile, 10% Owner Bain Capital Life Sciences Inv bought 0.45 million shares on Feb 12 ’24.
